United Therapeutics gets FDA clearance for Treprostinil-Iloprost SMI trial
UTHR•United Therapeutics received FDA clearance to begin a Phase 1 trial of Treprostinil-Iloprost SMI in healthy volunteers; a Phase 2 trial in pulmonary arterial hypertension patients is expected in 2027, contingent on successful Phase 1 results.
1. Trial plans
United Therapeutics received FDA clearance to begin a Phase 1 trial of Treprostinil-Iloprost SMI in healthy volunteers. A Phase 2 trial in pulmonary arterial hypertension patients is expected in 2027, contingent on successful Phase 1 results.
